Everolimus for the treatment of advanced renal cell carcinoma

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010 Sep-Oct;60(5):277-300
   PubMed Web of Science ®Google Scholar
• Beck SD, Patel MI, Synder ME, Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11:71-7
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Backik J, Murphy BA, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G, Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63
   PubMed Web of Science ®Google Scholar
• Yang JC, Childs R. Immunotherapy for renal cancer. J Clin Oncol 2006;24:5576-83
   PubMed Web of Science ®Google Scholar
• Garcia JA, Rini BL. Recent progress in the management of advanced RCC. CA Cancer J Clin 2007;57:112-25
   PubMed Web of Science ®Google Scholar
• Crespo J, Hall M. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2002;66:579-91
   PubMed Web of Science ®Google Scholar
• Dancey J. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-28
   PubMed Web of Science ®Google Scholar
• Bjornsti M, Houghton P. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
   PubMed Web of Science ®Google Scholar
• Beuvink I, Boulay A, Fumagalli S, The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59
   PubMed Web of Science ®Google Scholar
• Powis G, Kirkpatrick L. Hypoxia inducible factor-1 (alpha) as a cancer drug target. Mol Cancer Ther 2004;3:647-54
   PubMed Web of Science ®Google Scholar
• Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl 5):10-17
   PubMedGoogle Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colon cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Kris M, Natale R, Herbet R, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, inh symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Shepherd F, Rodrigues P, Ciuleanu T, Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Slamon D, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Bos J. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9
   PubMed Web of Science ®Google Scholar
• Kodiaki T, Woscholski R, Hallberg B, The activiation of phosphotidylinositol 3-kinase by RAS. Curr Biol 1994;4:798-806
   PubMedGoogle Scholar
• Nicholson K, Anderson N. The protein kinase B/AKT signaling pathway in human malignancy. Cell Signal 2002;14:381-95
   PubMed Web of Science ®Google Scholar
• deGraffenreid L, Friedrichs W, Russell D, Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant AKT activity. Clin Cancer Res 2004;10:8059-67
   PubMedGoogle Scholar
• Sansal I, Sellers W. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63
   PubMed Web of Science ®Google Scholar
• Escudier B, Thompson J. Mechanism of action of everolimus in RCC. Med Oncol 2009;26(Suppl 3):S32-9
   Google Scholar
• Pantuck A, Seligson D, Klatte T, Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 2007;109:2257-67
   PubMed Web of Science ®Google Scholar
• Kenerson H, Aicher L, True L, Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5646-50
   Google Scholar
• Dosquet C, Coudert M, Lepage E, Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997;3:2451-8
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Rasmuson T, Grankvist K, Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343-7
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Suzuki K, Koike H, Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23(6):4953-8
   PubMedGoogle Scholar
• Brugarolas J. Renal cell carcinoma-molecular pathways and therapies. N Engl J Med 2007;356:185-7
   PubMed Web of Science ®Google Scholar
• Patel P, Chadalavada R, Chaganti R, Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20
   PubMed Web of Science ®Google Scholar
• Kondo K, Kim W, Lechpammer M, Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:439-44. Available from: http://biology.plosjournals.org/archive/1545-1885/1/3/pdf/10.1371_journal.pbio.0000083-Lpdf
   Google Scholar
• Thomas G, Tran C, Mellinghoff I, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Faivre S, Burris H, Phase I pharmacokinetic and pharmacodynamics study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95
   PubMed Web of Science ®Google Scholar
• Amato R, Jac J, Giessinger S, A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. ACS 2009;115(1):2438-46
   Google Scholar
• Motzer R, Bacik J, Schwartz L, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63
   PubMed Web of Science ®Google Scholar
• Motzer R, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Motzer R, Escudier B, Oudard S, Phase 3 trial of everolimus for metastatic renal cell carcinoma. 2010 American Cancer Society. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Whorf R, Hainsworth J, Spigel D, Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26(Suppl): abstract 5010
   Google Scholar
• Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28(13):2131-6
   PubMed Web of Science ®Google Scholar
• Rosenberg J, Weinberg V, Claros C, Phase I study of sorafenib and RAD001 for metastatic clear cell RCC. J Clin Oncol 2008;26(Suppl): abstract 5009
   Google Scholar
• Giessinger S, Amato R, Jac J, A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) plus sorafenib for patients with metastatic renal cell cancer. J Clin Oncol 2008;26(Suppl): abstract 14603
   Google Scholar